The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis

BACKGROUND & AIMS: The immune checkpoint recently provides a new strategy for the immunotherapy of malignant tumors. However, the role in the immune microenvironment of DLBCL is not completely clear. METHODS: We detected the expression of PD-1, LAG-3, TIM-3, and TIGIT on TILs and on tumor cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jiajia, Pang, Xuelian, Li, Junna, Zhang, Wei, Cui, Wenli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763555/
https://www.ncbi.nlm.nih.gov/pubmed/36561512
http://dx.doi.org/10.3389/fonc.2022.1069378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763555/
https://www.ncbi.nlm.nih.gov/pubmed/36561512
http://dx.doi.org/10.3389/fonc.2022.1069378

Ejemplares similares